Vitamin D and asthma: Supplementation did not prevent condition from worsening, except in cases of severe deficiency - RCT

By Tingmin Koe contact

- Last updated on GMT

Vitamin D supplementation could prevent the worsening of lung problems in patients with vitamin D deficiency, a study has shown. ©Getty Images
Vitamin D supplementation could prevent the worsening of lung problems in patients with vitamin D deficiency, a study has shown. ©Getty Images

Related tags: Vitamin d, Asthma, Lung, New zealand

High dose of vitamin D supplementation did not prevent the worsening of lung problems, including asthma and COPD, except withing patients already suffering from severe deficiency, according to a RCT conducted in New Zealand.

Writing in Nutrients, ​researchers from Harvard Medical School, University of Cambridge, University of Otago and University of Auckland, said the benefits of vitamin D was “striking” ​in asthmatic and COPD patients with serum vitamin D at lower than 25nmol/L.

Unexpectedly, the researchers also observed that female patients who took high dose of vitamin D had 46% higher risk of the condition turning for the worse and had to take oral corticosteroid.

“Among women, the vitamin D group had worse lung function,”​ the researchers highlighted, although they believe that the results were most likely due to chance and urged for further research.

Over 5,200 people took part in this RCT, where they were randomised to take either a soft gel capsule containing 100,000 IU of vitamin D or placebo for about 3.3 years.

The subjects had to take two capsules of either vitamin D or placebo in the first month and one capsule monthly from the second month onwards.

From here, the researchers conducted a subgroup analysis on older adults with asthma or chronic obstructive pulmonary disease (COPD). The purpose was to find out the effects of vitamin D on their conditions.

In total, 775 subjects were analysed, with 214 suffering from asthma, 356 suffering from COPD, and 205 suffering from both conditions.

Amongst the intervention group, their serum level of vitamin D had increased from about 63nmol/L to 135 nmol/L, while that of the placebo group did not change.

Despite the increase in serum vitamin D levels, the intervention group did experience a lower incidence rate of oral corticosteroid prescription to curb their asthmatic or combined asthma/COPD symptoms. 

Amongst the intervention group, the incidence rate of oral corticosteroid prescription for asthma was 0.49, higher than the placebo group at 0.47.

Their incidence rate of oral corticosteroid prescription for asthma and COPD combined was 0.59, again, higher than the placebo group at 0.48.

Baseline matters

Vitamin D supplementation was useful only in subjects with low vitamin D levels at baseline, the researchers pointed out.

Amongst subjects with serum vitamin D at a baseline level of less than 25nmol/L, vitamin D supplementation had exerted a “protective effect” ​as seen in the lower incidence rate of oral corticosteroid prescription.

In this group of subjects, those from the intervention group recorded an incidence rate of 0.07, which was 10 times lower than that of the placebo group at 0.70.

Whereas in subjects with baseline vitamin D of 25 to 49.9 nmol/L, the incidence rate was 0.57 in the intervention group, higher than 0.42 seen in the placebo.

These findings were consistent with previous meta-analyses on vitamin D’s effects on asthma and COPD, the researchers said.

“In summary, although monthly high-dose vitamin D supplementation had no overall impact on exacerbations of asthma or COPD in these older adults, we found evidence of probable benefit among those with severe vitamin D deficiency,”​ they concluded.

The research was funded by the Health Research Council of New Zealand and the Accident Compensation Corporation of New Zealand.

 

Source: Nutrients

Effect of Monthly Vitamin D Supplementation on Preventing Exacerbations of Asthma or Chronic Obstructive Pulmonary Disease in Older Adults: Post Hoc Analysis of a Randomized Controlled Trial

https://doi.org/10.3390/nu13020521

Authors: Carolos A. Camargo, Jr and et al

Related news

Show more

Related products

show more

CuminUP60®: Small Dose at Max Effectiveness

CuminUP60®: Small Dose at Max Effectiveness

Chenland Nutritionals, Inc | 22-Mar-2021 | Technical / White Paper

CuminUP60® is Chenland’s clinically proven premier brand ingredient made with patented CGSF (Co-Grinding Solvent-Free) technology with high curcumin loads,...

Covid-19: A Game Changer for Probiotics

Covid-19: A Game Changer for Probiotics

Lumina Intelligence | 09-Feb-2021 | Technical / White Paper

This free whitepaper from Lumina Intelligence examines how the pandemic has impacted post-purchase consumer engagement with probiotics, the role of probiotics...

LalDéfense 85% yeast beta-glucan

LalDéfense 85% yeast beta-glucan

Lallemand Bio-Ingredients | 12-Nov-2020 | Infographic

LalDéfense is highly purified 85% yeast beta-glucan, suitable to support your natural defenses. Yeast beta-glucan has been extensively studied and proven...

MenaQ7® Vitamin K2: The Bone Support Solution

MenaQ7® Vitamin K2: The Bone Support Solution

NattoPharma USA, Inc. | 03-Sep-2020 | Data Sheet

Whether creating a product to fortify children’s bones as they grow or a formula to help adults stave off inevitable bone loss from ageing, MenaQ7® Vitamin...

Related suppliers

Follow us

Products

View more

Webinars

Nutra Champions Podcast

Nutra Champions Podcast